Finding S&P/ASX 200 Index (ASX: XJO) shares you can confidently tuck away for a decade isn't about chasing hype. It's about backing quality businesses with durable competitive advantages, global growth runways, and management teams that execute.
Two ASX 200 shares that tick those boxes are ResMed Inc (ASX: RMD) and Life360 Inc (ASX: 360). Both operate in structurally growing markets. Both ASX 200 shares have delivered strong long-term share price gains despite bouts of volatility. And both continue to attract positive analyst attention.
Image source: Getty Images
ResMed: Global healthcare powerhouse
This ASX 200 share develops cloud-connected medical devices and software for the treatment of sleep apnoea, chronic obstructive pulmonary disease, and other respiratory conditions. ResMed's devices and digital health ecosystem generate recurring revenue from masks, consumables, and monitoring software.
ResMed has long been a market darling. While the healthcare share price has seen swings over the past years, in the past 10 years, the company has gained 365% in value to $52 billion. After reaching an all-time high of $45.25 in August, ResMed has tumbled almost 20% to $36.34 at the time of writing.
However, the company's strengths are clear. The ASX 200 share holds a dominant position in sleep therapy, benefits from an ageing global population, and leverages data-driven technology to enhance patient outcomes. Its software platforms also deepen relationships with healthcare providers, creating high switching costs.
Recent earnings results showed continued revenue growth and resilient margins, driven by strong demand across its core sleep and respiratory segments. Management has highlighted ongoing product innovation and expanding digital integration as key drivers.
Risks include regulatory changes, competitive pressure, and currency movements, given its global footprint. Concerns about new obesity drugs reducing sleep apnoea incidence have also weighed on sentiment at times.
Still, many analysts remain constructive on the Aussie stock. TradingView data show that most market watchers see the ASX 200 share as a buy. They have set an average 12-month price target of $43.64, while the more optimistic target peaks at $52.48. This suggests a 44% upside at current price levels.
Life360: Scaling a digital ecosystem
Life360, by contrast, has been a higher-volatility growth story. The ASX 200 shares have surged dramatically over the past five years, rising more than 600% at one stage. But they have also experienced sharp pullbacks. In the past 6 months, the tech stock has dropped 55% to $20.38 at the time of writing.
Life360 operates a global digital safety platform focused on families. It offers location sharing, crash detection, roadside assistance, and identity protection services, primarily through subscription plans. The company has steadily grown monthly active users toward the 100 million mark, providing a strong funnel for paid conversions.
Its key strength lies in monetisation. Life360 continues converting free users into paying subscribers while expanding into higher-margin advertising through acquisitions and integrations.
Latest results showed continued revenue growth and rising subscription numbers, alongside improving profitability metrics. Management remains focused on balancing user growth with monetisation and cost discipline.
Risks include reliance on continued subscriber growth, privacy scrutiny around data usage, and competition from larger tech players. The stock also pays no dividend, reflecting its growth-first strategy.
Analyst sentiment remains broadly positive. Recent broker updates reiterate buy ratings, with price targets implying meaningful upside. Bell Potter just retained their buy rating with a trimmed price target of $40. This points to an upside of nearly 100% at current levels.
